회사 개요
PROCEPT BioRobotics Corporation, whose ticker symbol is PRCT, operates within the healthcare sector and specifically focuses on the medical devices industry by developing transformative surgical robotics solutions. The company specializes in urology, designing, manufacturing, and selling the AquaBeam Robotic System, which is an image-guided surgical robot intended for minimally invasive urologic procedures in both the United States and international markets. This surgical robotics firm employs 888 individuals and maintains a total market capitalization of $1.35 billion, while generating annual revenue of $308.05 million based on trailing twelve-month data. The combination of a $1.35 billion market cap and $308.05 million in revenue suggests that the company holds a significant position as a specialized player in the medical device space, indicating substantial market interest despite its current profitability challenges.
재무 건전성
PROCEPT BioRobotics Corporation reported trailing twelve-month revenue of $308.05 million, yet it recorded a net income of -$95,572,000 and an EBITDA of -$95.469 million, revealing a substantial gap between top-line sales and bottom-line earnings. This disparity between revenue and net income indicates a heavy cost structure where operating expenses, likely driven by research and development and manufacturing costs for the AquaBeam system, significantly erode operating profit. The company's free cash flow stands at -$23,916,124, which implies that the business is currently burning cash, a common characteristic for growth-stage medical device companies that prioritize reinvestment over cash preservation. The gross margin is reported at 63.7%, demonstrating high pricing power or efficiency in the cost of goods sold, whereas the operating margin of -40.6% and profit margin of -31.0% highlight significant operational inefficiencies or high overhead costs relative to revenue generation. On the balance sheet, the company holds $286.50 million in cash against $78.48 million in debt, resulting in a debt-to-equity ratio of 21.45, which presents a highly leveraged profile despite the substantial cash cushion available. The current ratio is a robust 6.84, indicating that the company possesses ample current assets to cover its short-term liabilities and maintain strong liquidity in the near term. Furthermore, the return on equity is -24.9% and the return on assets is -12.5%, metrics that reveal that management has yet to generate positive returns on shareholder capital or the asset base, reflecting the current phase of investment required to expand the robotic platform.
밸류에이션 평가
The trailing P/E ratio is listed as N/A due to the negative net income, while the forward P/E is reported as -27.03, implying that the market prices the stock based on future expectations of profitability that have not yet materialized in the current earnings cycle. The price-to-book ratio stands at 3.67, suggesting that the market values the company at a significant premium over its tangible book value, likely reflecting the intangible value of its intellectual property and the long-term potential of the AquaBeam Robotic System. Additionally, the price-to-sales ratio is 4.37 and the EV/EBITDA is -11.68, alternative valuation metrics that suggest investors are willing to pay a high multiple for revenue growth, even in the absence of current earnings, as these multiples often price in future market penetration in the urology sector. The stock has traded within a range defined by a 52-week high of $66.85 and a 52-week low of $19.35, and without the specific current share price provided in the data, the valuation context is derived entirely from these historical trading extremes which define the volatility envelope for the stock. The beta value is 0.93, indicating that the stock's price volatility tracks closely with the broader market, moving slightly less than the market average and suggesting a moderate level of systematic risk relative to large-cap peers.
Growth & Income
PROCEPT BioRobotics Corporation has demonstrated a year-over-year revenue growth rate of 11.9%, while the earnings growth is listed as N/A due to the company's recent losses, implying that top-line expansion is outpacing any potential earnings recovery in the current fiscal period. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings, or in this case, retained losses, are being reinvested back into the business to fund further product development and market expansion rather than being distributed to shareholders. This reinvestment strategy is typical for medical device firms in the growth phase, where capital is directed toward scaling the AquaBeam Robotic System's production and distribution capabilities rather than providing immediate income to investors. Overall, the company's profile is characterized by strong single-digit to double-digit revenue expansion coupled with a complete absence of dividend income, positioning it as a pure growth vehicle dependent on future operational leverage to eventually turn profitability around.